Most importantly, selinexor treatment (10 mg/kg, three times per week) leads to inhibition of tumor growth in ATC xenografts, which was associated with their decreased proliferation (Ki-67), blood vessel formation (CD31) and increased apoptosis (Tunel staining). The gene discussed is PECAM1; the disease is neoplasm.